Illumina (NASDAQ:ILMN) updated its FY20 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $6.80-7.00 for the period, compared to the Thomson Reuters consensus estimate of $6.98. Illumina also updated its FY 2019
After-Hours guidance to EPS.
Several equities research analysts have issued reports on the stock. Guggenheim assumed coverage on shares of Illumina in a research note on Friday, October 25th. They set a buy rating and a $350.00 target price on the stock. ValuEngine cut shares of Illumina from a buy rating to a hold rating in a research note on Friday, December 20th. UBS Group raised shares of Illumina from a neutral rating to a buy rating and set a $355.00 price target on the stock in a research report on Friday, January 3rd. Wells Fargo & Co initiated coverage on shares of Illumina in a research report on Tuesday, January 7th. They set an underweight rating and a $300.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Illumina in a research report on Thursday, November 14th. They set a buy rating and a $345.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $340.69.
Shares of NASDAQ:ILMN opened at $317.11 on Wednesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.82 and a quick ratio of 6.15. The firm has a market capitalization of $49.32 billion, a PE ratio of 55.44, a price-to-earnings-growth ratio of 2.26 and a beta of 1.05. The firm’s 50-day moving average is $326.73 and its two-hundred day moving average is $310.03. Illumina has a 1 year low of $263.30 and a 1 year high of $380.76.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.53. The company had revenue of $907.00 million for the quarter, compared to analyst estimates of $872.65 million. Illumina had a net margin of 28.14% and a return on equity of 22.05%. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.52 earnings per share. Analysts expect that Illumina will post 6.45 EPS for the current fiscal year.
In related news, SVP Susan H. Tousi sold 200 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $325.00, for a total transaction of $65,000.00. Following the sale, the senior vice president now directly owns 38,465 shares in the company, valued at $12,501,125. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Omead Ostadan sold 1,200 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $326.01, for a total transaction of $391,212.00. The disclosure for this sale can be found here. Insiders have sold 3,920 shares of company stock worth $1,262,212 over the last 90 days. Insiders own 0.38% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Read More: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.